Recipient of federal assistance · SHERMAN OAKS, CA

TRETHERA CORP

TRETHERA CORP received $3M in federal grants and other assistance in FY2026, on 4 actions, −40% vs FY2025. It has no federal contracts in the loaded years. Since FY2022: $13.8M. Its largest awarding agency was National Institutes of Health ($3M).

Assistance · FY2026
$3M
New awards
0
Actions
4
Since FY2022
$13.8M
UEI
QB66ZMAUF5P7
Location
SHERMAN OAKS, CA
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 368.2KFY2022
  2. 2.4MFY2023
  3. 3MFY2024
  4. 5.1MFY2025
  5. 3MFY2026

By type

  1. Grants$3M100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.395 · Cancer Treatment Research$1.2M38%
  2. 93.855 · Allergy and Infectious Diseases Research$995K33%
  3. 93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research$897.3K29%

Awarding agencies

  1. National Institutes of Health$3M100%
    Department of Health and Human Services

Largest awards

  1. DEVELOPMENT OF A NOVEL, TARGETED SMALL MOLECULE INHIBITOR OF THE NUCLEOSIDE SALVAGE PATHWAY THROUGH COMBINATORIAL MURINE STUDIES TO ENABLE…$2.3M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Aug 18, 2025 – Aug 5, 2026· R44CA302066
  2. DEVELOPMENT OF A NOVEL, TARGETED SMALL MOLECULE INHIBITOR OF THE NUCLEOSIDE SALVAGE PATHWAY TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS - PROJECT…$2M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 7, 2025 – Aug 11, 2026· R44AI188587
  3. DEVELOPMENT OF A NOVEL, TARGETED SMALL MOLECULE INHIBITOR OF THE NUCLEOSIDE SALVAGE PATHWAY TO TREAT CROHN'S DISEASE - PROJECT SUMMARY…$1.8M
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Sep 2, 2025 – Sep 17, 2026· R42DK138578
  4. DEVELOPMENT OF A NOVEL, TARGETED SMALL MOLECULE INHIBITOR OF THE NUCLEOSIDE SALVAGE PATHWAY TO TREAT OPTIC NEURITIS - PROJECT SUMMARY OPTIC…$1.6M
    93.867 · Vision Research· National Institutes of Health· Project grant· Sep 15, 2022 – May 21, 2026· R42EY034397

Subawards

Matched by Unique Entity ID: the first-tier subawards this organization reported as a prime recipient, and those primes reported paying it.

As a prime: who it pays · FY2026

No subawards reported as a prime in FY2026.

As a sub-recipient: who pays it · FY2026

No subawards reported to it in FY2026.

By fiscal year

  • FY2022: $185K paid out · $0 received
  • FY2023: $464.3K paid out · $0 received
  • FY2024: $910.4K paid out · $0 received

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 3, 2026, loaded Oct 3, 2026 · Subawards loaded from FY2021.

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2022–FY2026.